Nuvalent, Inc. (NUVL)

Market Cap	7.39B
Revenue (ttm)	n/a
Net Income (ttm)	-343.34M
Shares Out	72.10M
EPS (ttm)	-4.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,290
Open	102.51
Previous Close	102.97
Day's Range	102.51 - 102.51
52-Week Range	55.54 - 103.92
Beta	1.30
Analysts	Strong Buy
Price Target	121.45 (+18.48%)
Earnings Date	Oct 30, 2025

About NUVL

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: NUVL
• Website: https://www.nuvalent.com

Analyst Summary

According to 11 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price target is $121.45, which is an increase of 18.48% from the latest price.

Price Target

$121.45

(18.48% upside)

Analyst Consensus: Strong Buy